Pages that link to "Q44105601"

The following pages link to Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial (Q44105601):

Displaying 28 items.

• Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer (Q30424980) (← links)
• Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer (Q30452636) (← links)
• Pancreatic cancer: pathobiology, treatment options, and drug delivery (Q33749460) (← links)
• A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. (Q35050606) (← links)
• Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas (Q35226280) (← links)
• Chemoradiation in pancreatic adenocarcinoma: a literature review (Q35583949) (← links)
• Review article: chemotherapy for pancreatic cancer. (Q35599597) (← links)
• Paclitaxel and concurrent radiation in upper gastrointestinal cancers (Q35634812) (← links)
• Gemcitabine-induced severe pulmonary toxicity (Q35641366) (← links)
• Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer (Q35650631) (← links)
• Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. (Q35768026) (← links)
• Neoadjuvant GTX Chemotherapy and IMRT‐based chemoradiation for borderline resectable pancreatic cancer (Q35944817) (← links)
• Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: Results of feasibility study (Q36308891) (← links)
• Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience (Q36381222) (← links)
• Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma (Q36419779) (← links)
• Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. (Q36433785) (← links)
• Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model (Q36831339) (← links)
• Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells (Q36831348) (← links)
• Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review (Q37230970) (← links)
• Borderline resectable pancreatic cancer: on the edge of survival (Q37277969) (← links)
• Combined modality treatments in pancreatic cancer (Q37996462) (← links)
• Safety and efficacy evaluation of albumin-bound paclitaxel. (Q38190090) (← links)
• Oseltamivir-conjugated polymeric micelles prepared by RAFT living radical polymerization as a new active tumor targeting drug delivery platform. (Q38801444) (← links)
• Therapeutic designed poly (lactic-co-glycolic acid) cylindrical oseltamivir phosphate-loaded implants impede tumor neovascularization, growth and metastasis in mouse model of human pancreatic carcinoma. (Q38840619) (← links)
• Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers (Q40499821) (← links)
• Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer (Q44650366) (← links)
• Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy (Q80407725) (← links)
• Subsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapy (Q82974578) (← links)